Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China.
U.S. stocks traded mixed this morning, with the Dow Jones falling around 50 points on Tuesday Following the market opening Tuesday, the Dow traded down 0.18% to 34,035.79 while the NASDAQ rose 0.14% to 13,537.65. The S&P 500 also fell, dropping, 0.22% to 4,356.26.
Tharimmune Inc THAR has executed an exclusive worldwide licensing agreement with Avior Inc. to develop, market, and commercialize a clinical-stage asset,…